Kalaris Therapeutics Incorporation Registered shs Aktie

Kalaris Therapeutics Incorporation Registered shs ab 0 Euro bei Finanzen invest ordern (zzgl. Spreads)

WKN DE: A40YEN / ISIN: US4829291065

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
10.11.2026 19:16:45

Kalaris Therapeutics Reports Q3 Net Loss

(RTTNews) - Kalaris Therapeutics, Inc. (KLRS) on Tuesday, reported a lower net loss for the third quarter of 2026 compared with the same period in 2025, as operating expenses declined and other income remained positive.

The company posted a net loss of $11.026 million, or $0.46 per share, compared with a net loss of $11.894 million, or $0.64 per share, a year earlier.

Total operating expenses decreased to $11.811 million from $12.741 million. Research and development expenses fell to $8.344 million from $9.126 million, while general and administrative expenses declined to $3.467 million from $3.615 million.

For the first nine months of 2026, Kalaris reported a net loss of $33.397 million, or $1.40 per share, compared with a net loss of $33.440 million, or $2.41 per share, in the prior-year period. Total operating expenses increased to $36.030 million from $35.351 million.

KLRS is currently trading at $2.37, up $0.07 or 3.26 percent on the Nasdaq.

Nachrichten zu Kalaris Therapeutics Incorporation Registered shs

mehr Nachrichten
Keine Nachrichten verfügbar.

Analysen zu Kalaris Therapeutics Incorporation Registered shs

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel